Jeremy S. Abramson

Oncology
55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 207 publications

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Journal: Future oncology (London, England)
Published: July 06, 2026

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Journal: Advances in therapy
Published: May 08, 2026

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 27, 2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Journal: Blood
Published: April 01, 2026

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 13, 2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances
Published: February 24, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Journal: Blood advances
Published: December 08, 2025

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Journal: Blood advances
Published: December 08, 2025

Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.

Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.

Journal: Leukemia & lymphoma
Published: November 18, 2025

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

Journal: The Lancet. Haematology
Published: November 17, 2025
Showing 1-12 of 207

Last Updated: 09/26/2026